Skip to main content
OpenTrials
Completed

NCT Number: NCT00562302

Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure

BS-1053 A Prospective Randomized Multi-Centered Safety and Efficacy Evaluation of the Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedures

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Scottsdale Medical Imaging, Scottsdale, Arizona, United States

Loading trial locations.

About this study

This is a multi-centered, randomized trial in patients receiving lung biopsies. Patients will be randomized to either receive or not receive a Bio-Seal Biopsy Track Plug after a lung biopsy per standard hospital protocol. This study is designed to demonstrate safety and efficacy of the Bio-Seal Biopsy Track Plug in reducing pneumothorax rates post lung biopsy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient must meet all medical conditions for lung biopsy;
  • The patient must be at least 18 years of age;
  • The patient, or legal representative, must understand and provide written consent for the procedure;
  • The patient has a non-calcified, radiologically suspicious opacity or lung nodule, including a metastatic lung module, or mass of at least 1.0 cm in size; as determined by CT scan equipped with measurement software. Suspicious nodules observed by CT scan are defined as non-calcified masses with convex borders, not known to be stable. Suspicious nodules can also be defined as masses demonstrating opacity on chest x-ray that are suspicious by radiographic or clinical means and require biopsy.

Exclusion criteria

  • Patients with radiological findings of bullous emphysema located in the area of the anticipated biopsy and biopsy needle track;
  • Patients who cannot tolerate mild sedation, possibly secondary to poor respiratory status;
  • Female patients who are pregnant. Note: patients of childbearing potential must have a serum or urine pregnancy test no more than one week prior to the biopsy procedure, and be instructed not to have unprotected sexual intercourse after the test until the biopsy procedure is completed.
  • Patients who are uncooperative or cannot follow instructions.
  • Patients who are currently enrolled in another IDE or IND clinical investigation that has not completed the required follow-up period.

Treatment and study plan

Bio-Seal Plug

Device

Deployment of the Bio-Seal plug in needle track

Other names: Bio-Seal™ Lung Biopsy Tract System

Primary outcomes

  1. Incidence Rate of Treatment Success

    Time frame: 30 days

    Treatment success was defined as the absence of a pneumothorax at each of the three follow-up time periods (0-60 minutes, 24 hours and 30 days).

Secondary outcomes

  1. Incidence of Chest Tube Placement

    Time frame: 30 days

    A chest tube is the definitive initial treatment of a pneumothorax.

  2. Time to Ambulation

    Time frame: 30 days

  3. Incidence of Hospital Admissions for Pneumothorax

    Time frame: 30 day

  4. Incidence of Adverse Events Related to the Procedure and Device Effects

    Time frame: 30 Day

    Anticipated, device-related adverse events that were defined in the original protocol.

  5. Number of Participants With Additional Chest X-rays Needed

    Time frame: 30 day

  6. Participants Discharged Beyond Hospital's Standard of Care

    Time frame: 30-day

    Current standard of care for hospital discharge varies. Some institutions allow the patient to be discharged after a 3 hour wait. Others allow discharge after an x-ray indicates no pneumothorax. Since this study was randomized with control patients, the time to discharge beyond the hospital's standard of care was recorded to see if a trend for later discharge was apparent. This measure indicates the number of participants who were discharged later than their hospital's standard of care.

  7. Incidence of Adverse Events

    Time frame: 30 days

    Any treatment emergent adverse events (not considered device related by the investigators).

Sponsors and collaborators

Lead sponsor

Angiotech Pharmaceuticals

Industry

Registry information

Official study title

A Prospective, Randomized, Multi-centered Safety and Efficacy Evaluation of the Bio-Seal Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy

Important dates

Study start
2005
Primary completion
2008
Study completion
2008
First posted
Nov 22, 2007
Registry last updated
Mar 27, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.